The Rosen Law Firm, a global investor rights law firm, announced a September 30, 2025, deadline for potential lead plaintiffs in a class action lawsuit against Novo Nordisk A/S (NYSE: NVO). The firm represents investors who purchased Novo Nordisk securities between May 7, 2025, and July 28, 2025.
The lawsuit alleges that Novo Nordisk made misleading statements to investors regarding its growth potential. Specifically, the complaint contends that the company underestimated the impact of a market exception and overstated its ability to penetrate specific markets. These alleged misrepresentations, the suit claims, caused investors financial harm when the truth came to light.
Rosen Law Firm emphasizes the importance of choosing experienced legal counsel for such cases. The firm highlights its extensive experience in securities class action litigation, including a notable settlement against a Chinese company and consistent high rankings. They point out that many firms issuing such notices lack comparable experience and resources.
The firm stresses that investors who believe they suffered losses during the class period should consider their options. While serving as lead plaintiff involves directing the litigation, participation in any potential recovery is not contingent on this role. Investors can choose to retain their own counsel, remain absent class members, or take no action at this time.
Rosen Law Firm encourages anyone who believes they were affected to contact them before the September 30, 2025 deadline. The firm provided contact information including a phone number and email address for interested parties to seek further information. The firm also noted that no class has yet been certified, meaning individuals are not represented by counsel unless they retain one.
This information is for informational purposes only and does not constitute legal advice. Past successes do not guarantee future outcomes.
Related
